Making Advanced Therapies Affordable and Accessible: Two Strategic Approaches.
Level 5 - mechanism / opinion, no new human data
Level 5 by design analogy; non-empirical bioethics and policy commentary.
PubMed 40928580 · doi:10.1111/dewb.70004
What was done
This policy and bioethics analysis evaluates structural barriers that cause market withdrawal and access failure for advanced therapies. Using case examples such as Glybera and COVID-19 vaccine delivery, the paper outlines two strategic frameworks: a rehabilitative approach focused on post-development reforms (reimbursement models, manufacturing efficiency, regulatory streamlining) and a transformative approach focused on upstream research and development (local innovation, equitable intellectual property, and adaptive regulation).
What was found
The abstract reports no empirical data or quantitative metrics. It presents conceptual models contrasting system-reforming approaches with upstream structural restructuring to mitigate commercial development failure and improve global distribution.
Why it matters
Advanced therapies face severe commercialization and distribution hurdles that frequently prevent patient access; this framework provides structured policy options to integrate access considerations throughout the product lifecycle.
Limits
The paper is a conceptual policy commentary with no empirical data, cost-effectiveness modeling, or systematic review methodology. Real-world implementation feasibility and quantitative impacts of the proposed strategies are not evaluated.
Cited by
- context Top adenoviral-vectored COVID-19 vaccines cost as little as $2 per dose, compared to typical gene therapies that cost around $2 million.